• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference

by Rakovina Therapeutics | Oct 16, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, October 16, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new preclinical...

Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

by Rakovina Therapeutics | Oct 7, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, September 4, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive...

Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

by Rakovina Therapeutics | Sep 17, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, September 4, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that...

Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

by Rakovina Therapeutics | Aug 29, 2025 | Uncategorized

All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, August 28, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing...

Rakovina Therapeutics Announces Stock Option Grants

by Rakovina Therapeutics | Aug 29, 2025 | Uncategorized

DOWNLOAD VANCOUVER, BC, July 29, 2025 – Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is...

Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

by Rakovina Therapeutics | Aug 26, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, August 26, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through Al-powered drug discovery, today announced...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media